Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74


Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.

Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG, Newton DL.

J Proteome Res. 2010 Aug 6;9(8):4016-27. doi: 10.1021/pr100194d. Erratum in: J Proteome Res. 2011 Apr 1;10(4):2128.


Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH.

J Pharm Biomed Anal. 2010 Sep 5;52(5):714-20. doi: 10.1016/j.jpba.2010.02.020. Epub 2010 Feb 23.


Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.

Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.

Mol Pharmacol. 2006 Sep;70(3):1109-20. Epub 2006 Jun 23.


Proteomics analysis of kojic acid treated A375 human malignant melanoma cells.

Nawarak J, Huang-Liu R, Kao SH, Liao HH, Sinchaikul S, Chen ST, Cheng SL.

J Proteome Res. 2008 Sep;7(9):3737-46. doi: 10.1021/pr7008737. Epub 2008 Jul 17.


Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer.

Rho JH, Qin S, Wang JY, Roehrl MH.

J Proteome Res. 2008 Jul;7(7):2959-72. doi: 10.1021/pr8000892. Epub 2008 Jun 13.


ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

Jossé R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y.

Cancer Res. 2014 Dec 1;74(23):6968-79. doi: 10.1158/0008-5472.CAN-13-3369. Epub 2014 Sep 30.


Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.

Zhang X, Wang R, Zhao L, Lu N, Wang J, You Q, Li Z, Guo Q.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1276-81. doi: 10.1016/j.bmcl.2011.10.019. Epub 2011 Oct 24.


Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5.


Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.

Mears R, Craven RA, Hanrahan S, Totty N, Upton C, Young SL, Patel P, Selby PJ, Banks RE.

Proteomics. 2004 Dec;4(12):4019-31.


Proteomic identification of differentially expressed proteins in aortic wall of patients with ruptured and nonruptured abdominal aortic aneurysms.

Urbonavicius S, Lindholt JS, Vorum H, Urbonaviciene G, Henneberg EW, Honoré B.

J Vasc Surg. 2009 Feb;49(2):455-63. doi: 10.1016/j.jvs.2008.08.097. Epub 2008 Nov 28.


Characterization of human melanoma cell lines and melanocytes by proteome analysis.

Caputo E, Maiorana L, Vasta V, Pezzino FM, Sunkara S, Wynne K, Elia G, Marincola FM, McCubrey JA, Libra M, Travali S, Kane M.

Cell Cycle. 2011 Sep 1;10(17):2924-36. Epub 2011 Sep 1.


Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Beck DE, Abdelmalak M, Lv W, Reddy PV, Tender GS, O'Neill E, Agama K, Marchand C, Pommier Y, Cushman M.

J Med Chem. 2015 May 14;58(9):3997-4015. doi: 10.1021/acs.jmedchem.5b00303. Epub 2015 Apr 24.


Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2009 Jul;8(7):1878-84. doi: 10.1158/1535-7163.MCT-09-0016. Epub 2009 Jul 7.


Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines.

Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, Iizuka N, Ueyama Y, Nakamura K.

Proteomics. 2005 Mar;5(4):1024-32.


Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup language (XML)-based database.

Yoshida Y, Miyazaki K, Kamiie J, Sato M, Okuizumi S, Kenmochi A, Kamijo K, Nabetani T, Tsugita A, Xu B, Zhang Y, Yaoita E, Osawa T, Yamamoto T.

Proteomics. 2005 Mar;5(4):1083-96.


Proteomic analysis identifies oxidative stress induction by adaphostin.

Stockwin LH, Bumke MA, Yu SX, Webb SP, Collins JR, Hollingshead MG, Newton DL.

Clin Cancer Res. 2007 Jun 15;13(12):3667-81.


Comparative proteomic analysis of colon cancer cell HCT-15 in response to all-trans retinoic acid treatment.

Zhao J, Wen G, Ding M, Pan JY, Yu ML, Zhao F, Weng XL, Du JL.

Protein Pept Lett. 2012 Dec;19(12):1272-80.


Supplemental Content

Support Center